Intuitive Surgical Stock Price Correction Analysis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 16 hours ago
0mins
Source: Fool
- Market Performance Correction: Intuitive Surgical's stock has fallen over 30% since early 2025; however, Wall Street analysts remain optimistic, with an average price target of $570, indicating a potential rebound of over 30% from current depressed levels.
- Strong Business Model: As a medical device company focused on surgical robots, Intuitive Surgical had 11,395 da Vinci systems installed globally by Q1 2026, reflecting a 12% year-over-year increase, showcasing robust market demand.
- Surgery Demand Growth: The number of surgeries performed by da Vinci robots rose 17% year-over-year, indicating broad demand for robotic surgery, with approximately 75% of revenue derived from instruments and services, creating stable income streams.
- Optimistic Long-Term Outlook: Despite a current P/E ratio of 51, down from a five-year average of 70, Intuitive Surgical is poised to benefit from new system sales and increasing patient demand for robotic surgery, with significant market opportunities likely over the next decade.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ISRG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ISRG
Wall Street analysts forecast ISRG stock price to rise
20 Analyst Rating
16 Buy
4 Hold
0 Sell
Strong Buy
Current: 423.630
Low
575.00
Averages
637.32
High
740.00
Current: 423.630
Low
575.00
Averages
637.32
High
740.00
About ISRG
Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Intuitive Surgical Stock Price Correction Analysis
- Market Performance Correction: Intuitive Surgical's stock has fallen over 30% since early 2025; however, Wall Street analysts remain optimistic, with an average price target of $570, indicating a potential rebound of over 30% from current depressed levels.
- Strong Business Model: As a medical device company focused on surgical robots, Intuitive Surgical had 11,395 da Vinci systems installed globally by Q1 2026, reflecting a 12% year-over-year increase, showcasing robust market demand.
- Surgery Demand Growth: The number of surgeries performed by da Vinci robots rose 17% year-over-year, indicating broad demand for robotic surgery, with approximately 75% of revenue derived from instruments and services, creating stable income streams.
- Optimistic Long-Term Outlook: Despite a current P/E ratio of 51, down from a five-year average of 70, Intuitive Surgical is poised to benefit from new system sales and increasing patient demand for robotic surgery, with significant market opportunities likely over the next decade.
See More
Intuitive Surgical Stock Nears 52-Week Lows Amid Analyst Optimism
- Stock Decline: Intuitive Surgical's stock has fallen 30% from its recent peak and is trading near 52-week lows; however, analysts remain optimistic, projecting a recovery to $570, representing over a 30% rebound from current depressed levels.
- Surgery Demand Growth: By the end of Q1 2026, the number of installed da Vinci surgical systems reached 11,395, a 12% increase year-over-year, indicating strong demand for robotic surgery that is driving revenue growth for the company.
- Stable Revenue Structure: Approximately 75% of the company's revenue comes from the sale of surgical instruments, accessories, and services, which are annuity-like income streams, suggesting that even a slowdown in new system sales would not derail long-term prospects.
- Broad Market Outlook: Despite a current P/E ratio of 51, down from a five-year average of 70, Intuitive Surgical's leadership in medical technology and ongoing market demand indicate significant growth potential over the next decade, making it an attractive option for aggressive growth investors.
See More
TDG vs ISRG Stock Performance Comparison
- TDG Stock Movement: TDG is currently trading up approximately 0.9%, indicating a degree of market confidence that may attract investor interest in its future growth potential.
- ISRG Stock Performance: ISRG is down about 0.5%, reflecting market concerns regarding its recent performance, which could impact investor confidence and future capital inflows.
- Market Comparison Analysis: The contrasting stock movements of TDG and ISRG on the same trading day highlight differing market expectations for the future development of the two companies, potentially influencing investors' asset allocation decisions.
- Investor Sentiment: The rise in TDG may draw more investor attention, while the decline in ISRG could lead investors to reassess their portfolios, reflecting varying market perceptions of the medical device sector.
See More
Intuitive Appoints New Chief Commercial Officer to Drive Growth
- Executive Appointment: Intuitive announces the promotion of Taylor Patton, Global Senior Vice President, to Chief Commercial and Marketing Officer effective July 1, aiming to enhance the company's global market impact and customer support capabilities.
- Leadership Transition: Former CMO Henry Charlton will transition to Senior Vice President of Global Business Operations, continuing to support the company's global expansion and ensuring customers receive world-class support and service.
- Experienced Leader: With nearly two decades at Intuitive, Patton has built and scaled teams across multiple business units, and his extensive experience with the da Vinci, Ion, and Digital platforms will enhance the quality and consistency of customer support.
- Strategic Commitment: Patton is dedicated to advancing the company's efforts in providing better healthcare, helping customers achieve the Quintuple Aim by reducing treatment costs while improving patient outcomes and satisfaction.
See More
Analysis of Trump's Drug Pricing Policy Impact
- Drug Pricing Policy: Trump's Most-Favored-Nation policy aims to cap U.S. drug prices to match those of other developed nations, potentially impacting government programs like Medicare and leading to decreased sales and profits for drugmakers.
- Strong Revenue Outlook: Despite challenges from drug price negotiations, Johnson & Johnson expects to achieve $100.8 billion in revenue for 2023, reflecting a 7% year-over-year increase and demonstrating resilience in its diversified healthcare portfolio.
- New Product Development: Johnson & Johnson is seeking U.S. approval for its robotic-assisted surgery device, the Ottava system, which, despite competition, could benefit from the growing demand for minimally invasive procedures due to an aging population.
- Acquisition and Growth: Roche's acquisition of SAGA Diagnostics for up to $595 million aims to strengthen its position in the molecular residual disease testing market, which is one of the fastest-growing areas in diagnostics, potentially offsetting pressures from drug pricing policies.
See More
Trump's Drug Price Policy Could Impact Pharma Profits
- Drug Pricing Policy: Trump's Most-Favored-Nation policy aims to limit the prices the U.S. government pays for certain drugs, potentially triggering a domino effect on pharmaceutical companies' sales and profits in the world's largest pharmaceutical market.
- Strong Revenue Outlook: Despite challenges from drug price negotiations, Johnson & Johnson expects to achieve $100.8 billion in revenue this year, reflecting a 7% year-over-year increase and showcasing its resilience and adaptability in the diversified healthcare sector.
- Acquisition and Innovation: Roche's acquisition of SAGA Diagnostics, costing up to $595 million, aims to strengthen its position in the rapidly growing molecular residual disease testing market for cancer, which is expected to drive growth in its diagnostics business.
- Diversification Advantage: The diversified portfolios of Johnson & Johnson and Roche enable them to maintain competitiveness under Trump's drug pricing policies, particularly through ongoing innovation and investment in medical devices and diagnostics.
See More
Intuitive Surgical Stock Price Correction Analysis
- Market Performance Correction: Intuitive Surgical's stock has fallen over 30% since early 2025; however, Wall Street analysts remain optimistic, with an average price target of $570, indicating a potential rebound of over 30% from current depressed levels.
- Strong Business Model: As a medical device company focused on surgical robots, Intuitive Surgical had 11,395 da Vinci systems installed globally by Q1 2026, reflecting a 12% year-over-year increase, showcasing robust market demand.
- Surgery Demand Growth: The number of surgeries performed by da Vinci robots rose 17% year-over-year, indicating broad demand for robotic surgery, with approximately 75% of revenue derived from instruments and services, creating stable income streams.
- Optimistic Long-Term Outlook: Despite a current P/E ratio of 51, down from a five-year average of 70, Intuitive Surgical is poised to benefit from new system sales and increasing patient demand for robotic surgery, with significant market opportunities likely over the next decade.
See More
Intuitive Surgical Stock Nears 52-Week Lows Amid Analyst Optimism
- Stock Decline: Intuitive Surgical's stock has fallen 30% from its recent peak and is trading near 52-week lows; however, analysts remain optimistic, projecting a recovery to $570, representing over a 30% rebound from current depressed levels.
- Surgery Demand Growth: By the end of Q1 2026, the number of installed da Vinci surgical systems reached 11,395, a 12% increase year-over-year, indicating strong demand for robotic surgery that is driving revenue growth for the company.
- Stable Revenue Structure: Approximately 75% of the company's revenue comes from the sale of surgical instruments, accessories, and services, which are annuity-like income streams, suggesting that even a slowdown in new system sales would not derail long-term prospects.
- Broad Market Outlook: Despite a current P/E ratio of 51, down from a five-year average of 70, Intuitive Surgical's leadership in medical technology and ongoing market demand indicate significant growth potential over the next decade, making it an attractive option for aggressive growth investors.
See More
TDG vs ISRG Stock Performance Comparison
- TDG Stock Movement: TDG is currently trading up approximately 0.9%, indicating a degree of market confidence that may attract investor interest in its future growth potential.
- ISRG Stock Performance: ISRG is down about 0.5%, reflecting market concerns regarding its recent performance, which could impact investor confidence and future capital inflows.
- Market Comparison Analysis: The contrasting stock movements of TDG and ISRG on the same trading day highlight differing market expectations for the future development of the two companies, potentially influencing investors' asset allocation decisions.
- Investor Sentiment: The rise in TDG may draw more investor attention, while the decline in ISRG could lead investors to reassess their portfolios, reflecting varying market perceptions of the medical device sector.
See More
Intuitive Appoints New Chief Commercial Officer to Drive Growth
- Executive Appointment: Intuitive announces the promotion of Taylor Patton, Global Senior Vice President, to Chief Commercial and Marketing Officer effective July 1, aiming to enhance the company's global market impact and customer support capabilities.
- Leadership Transition: Former CMO Henry Charlton will transition to Senior Vice President of Global Business Operations, continuing to support the company's global expansion and ensuring customers receive world-class support and service.
- Experienced Leader: With nearly two decades at Intuitive, Patton has built and scaled teams across multiple business units, and his extensive experience with the da Vinci, Ion, and Digital platforms will enhance the quality and consistency of customer support.
- Strategic Commitment: Patton is dedicated to advancing the company's efforts in providing better healthcare, helping customers achieve the Quintuple Aim by reducing treatment costs while improving patient outcomes and satisfaction.
See More
Analysis of Trump's Drug Pricing Policy Impact
- Drug Pricing Policy: Trump's Most-Favored-Nation policy aims to cap U.S. drug prices to match those of other developed nations, potentially impacting government programs like Medicare and leading to decreased sales and profits for drugmakers.
- Strong Revenue Outlook: Despite challenges from drug price negotiations, Johnson & Johnson expects to achieve $100.8 billion in revenue for 2023, reflecting a 7% year-over-year increase and demonstrating resilience in its diversified healthcare portfolio.
- New Product Development: Johnson & Johnson is seeking U.S. approval for its robotic-assisted surgery device, the Ottava system, which, despite competition, could benefit from the growing demand for minimally invasive procedures due to an aging population.
- Acquisition and Growth: Roche's acquisition of SAGA Diagnostics for up to $595 million aims to strengthen its position in the molecular residual disease testing market, which is one of the fastest-growing areas in diagnostics, potentially offsetting pressures from drug pricing policies.
See More
Trump's Drug Price Policy Could Impact Pharma Profits
- Drug Pricing Policy: Trump's Most-Favored-Nation policy aims to limit the prices the U.S. government pays for certain drugs, potentially triggering a domino effect on pharmaceutical companies' sales and profits in the world's largest pharmaceutical market.
- Strong Revenue Outlook: Despite challenges from drug price negotiations, Johnson & Johnson expects to achieve $100.8 billion in revenue this year, reflecting a 7% year-over-year increase and showcasing its resilience and adaptability in the diversified healthcare sector.
- Acquisition and Innovation: Roche's acquisition of SAGA Diagnostics, costing up to $595 million, aims to strengthen its position in the rapidly growing molecular residual disease testing market for cancer, which is expected to drive growth in its diagnostics business.
- Diversification Advantage: The diversified portfolios of Johnson & Johnson and Roche enable them to maintain competitiveness under Trump's drug pricing policies, particularly through ongoing innovation and investment in medical devices and diagnostics.
See More
